Kenvue
Corporate brand
UnclaimedA global consumer health company operating major brands in over-the-counter medicines, skin health, oral care, and personal care.
Last updated August 21, 2026
AI crawler reads
No AI crawler has read this profile yet.
Overview
Kenvue is an American consumer health company formed from Johnson & Johnson’s former consumer health division. Its portfolio includes brands such as Tylenol, Neutrogena, Listerine, Johnson’s, Aveeno, Band-Aid, Zyrtec, Motrin, Visine, and Rogaine. The business spans self-care medicines, skin health and beauty, oral care, baby care, wound care, and other everyday consumer health categories. Johnson & Johnson announced the separation of its consumer health operations in November 2021, presenting the move as a way to give the consumer business greater strategic focus while allowing Johnson & Johnson to concentrate on pharmaceuticals and medical devices. The business was incorporated in Delaware in February 2022 under the provisional name JNTL, Inc. The Kenvue name was announced in September 2022. It combines “ken,” associated with knowledge, with “vue,” intended to suggest sight or perspective. Kenvue completed an initial public offering on the New York Stock Exchange in May 2023 under the symbol KVUE. The offering priced shares at $22 and raised approximately $3.8 billion, while Johnson & Johnson initially retained a large majority stake. Johnson & Johnson later conducted an exchange offer in July 2023 to complete the separation of the two companies. Kenvue joined the S&P 500 Dividend Aristocrats index in August 2023. The company’s commercial model relies on recognizable, widely distributed consumer brands rather than a single flagship product. Its self-care portfolio includes pain relief, allergy and cold medicines, gastrointestinal products, smoking-cessation products, and eye care. Its beauty and personal-care activities include facial care, acne care, body care, hair regrowth, and skin moisturization. Oral care is led by Listerine, while baby care is associated particularly with Johnson’s. Kenvue also sells wound-care products through Band-Aid and topical medicines through brands including Neosporin and Trosyd. Kenvue has faced investor scrutiny since becoming public. A securities class action filed in 2023 alleged that the company’s registration materials did not adequately describe risks and potential litigation concerning phenylephrine-containing products and questions about the ingredient’s efficacy. The company also experienced leadership and strategic changes in 2025. Thibaut Mongon, its initial chief executive, was terminated in July 2025, after activist investor Starboard Value acquired a stake and its chief executive Jeffrey Smith joined Kenvue’s board. Kirk Perry was subsequently named interim chief executive and, according to the supplied reference material, became permanent chief executive in November 2025. In November 2025, Kimberly-Clark announced an agreement to acquire Kenvue for an enterprise value reported at approximately $48.7 billion. The proposed transaction would combine Kenvue’s consumer health portfolio with Kimberly-Clark brands including Kleenex, Kotex, Huggies, and Softex. Completion was expected in the second half of 2026, subject to customary conditions and approvals. Until completion, Kenvue remains a separately listed public company.
History
Kenvue originated in Johnson & Johnson’s consumer health division, a business built around household and over-the-counter brands rather than prescription medicines or medical devices. On November 12, 2021, Johnson & Johnson announced that it would separate the division into a new company. The proposed separation included brands such as Aveeno, Band-Aid, Neutrogena, Tylenol, Johnson’s, and Listerine. Johnson & Johnson said the change would allow the consumer operation to pursue its own priorities while the parent company focused on pharmaceuticals and medical devices. The separation occurred during a period when several large healthcare companies were reshaping or divesting consumer operations. It also followed reputational and litigation challenges associated with Johnson & Johnson, including disputes involving opioids and talc products. The consumer business had substantial brand recognition but a different growth and capital profile from Johnson & Johnson’s pharmaceutical and medical-device units. The planned separation therefore served both an organizational and strategic purpose. The new company was incorporated in Delaware in February 2022 under the provisional name JNTL, Inc. It was initially based in the Skillman section of Montgomery Township, New Jersey. In September 2022, Johnson & Johnson announced the Kenvue name. The name was described as combining a term associated with knowledge with a word suggesting vision or perspective. At that stage, the business employed approximately 22,000 people. Kenvue filed for an initial public offering with the U.S. Securities and Exchange Commission in January 2023. The offering took place on May 4, 2023. Approximately 170 million shares were offered at $22 each, raising about $3.8 billion and giving the company an initial equity valuation of roughly $41 billion. Johnson & Johnson retained close to 91 percent of Kenvue after the offering. The listing provided a public valuation for a major consumer health portfolio and occurred amid a subdued U.S. IPO market. In July 2023, Johnson & Johnson launched an exchange offer through which its shareholders could exchange Johnson & Johnson common stock for Kenvue shares. This transaction completed the operational separation and substantially changed the shareholder relationship between the two companies. Kenvue was added to the S&P 500 Dividend Aristocrats index in August 2023. Kenvue’s business is organized around categories including self-care, skin health and beauty, essential health, oral care, and baby care. Its portfolio includes analgesics and fever reducers, allergy and cold remedies, gastrointestinal products, smoking-cessation products, eye care, dermatological treatments, facial care, moisturizers, hair-regrowth products, wound care, and oral hygiene. The company’s broad brand portfolio gives it distribution across pharmacies, supermarkets, mass retailers, e-commerce channels, and healthcare-related outlets in numerous markets. The company’s first chief executive was Thibaut Mongon. Kenvue later faced investor concerns connected with disclosures about phenylephrine products. A securities class action filed in October 2023 alleged that Kenvue’s registration statement did not adequately disclose risks, potential litigation, and efficacy-related issues involving phenylephrine. The allegations were contested matters rather than established findings in the supplied reference material. In 2025, activist investment firm Starboard acquired a stake in Kenvue, and Starboard chief executive Jeffrey Smith joined the company’s board. Kenvue terminated Mongon in July 2025 and began a review of its strategy. Kirk Perry was named interim chief executive and was subsequently identified in the reference material as the permanent CEO from November 2025. On November 3, 2025, Kimberly-Clark announced an agreement to acquire Kenvue. The proposed combination would bring Kenvue’s consumer health brands together with Kimberly-Clark’s household and personal-care brands. The reported enterprise value was approximately $48.7 billion. Kimberly-Clark shareholders were expected to own about 54 percent of the combined company and Kenvue shareholders about 46 percent. Completion was expected in the second half of 2026, meaning the transaction remained pending in the supplied material.
- 2025
Leadership transition and strategy review
[1]Kenvue changes chief executive leadership after activist investor involvement and begins a strategic review.
- 2025
Kimberly-Clark acquisition agreement
[1]Kimberly-Clark announces a proposed acquisition of Kenvue for an enterprise value of approximately $48.7 billion.
- 2023
Initial public offering
[1]Kenvue lists on the New York Stock Exchange under KVUE, pricing its IPO at $22 per share and raising approximately $3.8 billion.
- 2023
Johnson & Johnson exchange offer completes separation
[1]Johnson & Johnson launches an exchange offer allowing shareholders to exchange parent-company shares for Kenvue shares.
- 2023
Added to S&P 500 Dividend Aristocrats index
[1]Kenvue is added to the S&P 500 Dividend Aristocrats index.
- 2022
JNTL, Inc. is incorporated
[1]The future Kenvue business is incorporated in Delaware under the provisional name JNTL, Inc.
- 2022
Kenvue name announced
[1]Johnson & Johnson introduces Kenvue as the name of the planned standalone consumer health company.
- 2021
Johnson & Johnson announces consumer health separation
[1]Johnson & Johnson announces that its consumer health division will become an independent company.
Products and positioning
Science-led, mass-market consumer health and personal-care portfolio built around trusted, globally distributed brands.
Over-the-counter pain relief
Tylenol
A major analgesic and fever-reduction brand marketed in multiple dosage forms and markets. Tylenol is one of Kenvue’s most prominent self-care franchises and is associated primarily with acetaminophen-based products.
Oral care
Listerine
An international mouthwash and oral-care brand offering products designed for rinsing, breath care, plaque control, and broader daily oral-hygiene routines.
Skin health and beauty
Neutrogena
A skin-care and beauty brand known for facial cleansers, moisturizers, acne-care products, sunscreens, and other dermatological or cosmetic items. It serves both everyday skin-care and more targeted treatment routines.
Baby care
Johnson's
Kenvue’s baby-care portfolio includes cleansers, shampoos, lotions, oils, and related products formulated and marketed for infants and families. The brand also has personal-care extensions in some markets.
Skin care
Aveeno
A skin-care brand centered on moisturization and products for dry or sensitive skin. Its portfolio includes body lotions, facial care, cleansing products, and other everyday dermatological-care offerings.
Wound care
Band-Aid
A wound-care brand offering adhesive bandages and related products for minor cuts, abrasions, blisters, and everyday first-aid needs.
Allergy medicine
Zyrtec
An over-the-counter allergy brand offering products for symptoms associated with allergic rhinitis and related conditions in markets where the brand is sold.
Hair-regrowth treatment
Rogaine
A topical hair-regrowth brand positioned around products for hereditary hair loss and related consumer hair-care concerns.
Eye care
Visine
An eye-care brand offering over-the-counter products for common eye symptoms and irritation, subject to the formulations and regulatory permissions of individual markets.
Over-the-counter pain relief
Motrin
A consumer pain-relief brand associated primarily with ibuprofen products and positioned for relief of common aches, pains, and fever.
Controversies
2023
Phenylephrine disclosure securities litigation
A securities class action filed in the United States District Court for the District of New Jersey alleged that Kenvue’s registration statement contained misleading statements or omissions concerning internal controls, financial reporting, and risks or potential litigation connected with phenylephrine products and questions about their efficacy. The supplied material describes allegations and investor losses, not a final adjudication.
Brand decisions
2025
Leadership change and strategic reviewStrategyBackground
Activist investor Starboard acquired a stake in Kenvue, and Starboard chief executive Jeffrey Smith joined the board.
Action taken
Kenvue terminated Thibaut Mongon as chief executive and initiated a review of company strategy.
Aftermath
Kirk Perry became interim chief executive and was later identified as the permanent CEO in November 2025.
2025
Proposed acquisition by Kimberly-ClarkM&ABackground
Kimberly-Clark sought to combine its household and personal-care brands with Kenvue’s global consumer health portfolio.
Action taken
Announced a cash-and-stock agreement to acquire Kenvue at an enterprise value of approximately $48.7 billion.
Aftermath
The transaction was expected to close in the second half of 2026, subject to customary conditions and approvals.
Proposed enterprise value. Approximately US$48.7 billion (November 2025 announcement)
2023
Initial public offeringProduct launchBackground
Kenvue entered the public market as a large, established consumer-health portfolio during a period of reduced U.S. IPO activity.
Action taken
Priced approximately 170 million shares at $22 each on the New York Stock Exchange under KVUE.
Aftermath
The offering raised approximately $3.8 billion, while Johnson & Johnson initially retained close to 91 percent ownership.
IPO proceeds. Approximately US$3.8 billion raised (May 2023)
2023
Complete separation through exchange offerM&ABackground
Following the IPO, Johnson & Johnson still held most Kenvue shares and needed to complete the planned separation.
Action taken
Launched an exchange offer allowing Johnson & Johnson shareholders to exchange parent-company shares for Kenvue shares.
Aftermath
The transaction completed the intended corporate separation between the two companies.
2021
Separate consumer health from Johnson & JohnsonStrategyBackground
Johnson & Johnson sought to give its consumer health business a distinct strategic and operating focus while concentrating the parent company on pharmaceuticals and medical devices.
Action taken
Announced a plan to establish the consumer health division as a standalone company.
Aftermath
The new business became Kenvue and later entered public markets, followed by a full share-based separation from Johnson & Johnson.
Recent events
- Unconfirmed
Reported
Kimberly-Clark acquires Kenvue[3]
Kimberly-Clark acquired Kenvue in a deal with an estimated enterprise value of almost $49 billion.
Reported
Essity agrees to acquire Kenvue's feminine care business in Brazil[4]
Essity has entered into an agreement to acquire Kenvue's feminine care business in Brazil, including the Carefree, Sempre Livre and o.b. brands, for USD 284m on a cash and debt-free basis. The transaction is subject to regulatory approval in Brazil and other customary closing conditions, including completion of the Kimberly-Clark and Kenvue transaction, and is expected to close in the second quarter of 2027.
Sources6 sources
Cite this profile: Cite the canonical profile. /brand-wiki/kenvue · Editorial policy · How profiles are compiled